tbuckley/cabot-search huggingface dataset:
Counseling Patients on Photoprotection
Authors: Dennis A. Porto, Steven Q. Wang, Henry W. Lim
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
18 F-FDG PET Interim and Determination of Cellular Origin By Immunohistochemistry Identify a Group of Very Good Prognosis in Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era
Authors: Luis Alberto de Padua Covas Lage, Renata Oliveira Costa, Abrahão Elias Hallack Neto, Sheila Siqueira, Rodrigo Santucci, Henrique Moura de Paula, Juliana Pereira
Journal: Blood (2014)
De Novo Synthesis &amp; Storage of Human Factor VIII In Platelets Reduces Bleeding In Canine Hemophilia A
Authors: Lily M. Du, Helen W.G. Franck, Elizabeth P. Merricks, Paquita Nurden, Eric S. Jensen, Sandra L. Haberichter, Troy B. Hawkins, Paula M. Jacobi, Juan Fang, Timothy C. Nichols, Sevasti B. Koukouritaki, Qizhen Shi, Robert R. Montgomery, Kenneth Cornetta, Alan T. Nurden, David A. Wilcox
Journal: Blood (2010)
The histone Deacetylase Inhibitor Givinostat in Combination with Sorafenib Induces Reactive Oxygen Species (ROS) Generation and Exerts Potent Antitumor Effects in NOD/SCID Mice with Hodgkin Lymphoma Cell Line Xenografts
Authors: Silvia L Locatelli, Anna Guidetti, Loredana Cleris, Silvia Tartari, Alessandro M. Gianni, Andrea Anichini, Carmelo Carlo-Stella
Journal: Blood (2012)
Prognostic and Functional Relevance of Aberrant Microrna-9/9* Expression in Acute Myeloid Leukemia.
Authors: Su Ming Sun, Katarzyna Nowek, Lars Bullinger, Menno Dijkstra, Peter J. M. Valk, Hartmut Dohner, Stefan J. Erkeland, Bob Lowenberg, Mojca Jongen-Lavrencic
Journal: Blood (2012)
SYK Inhibition Targets CD38−Mediated Survival and Proliferation Signals in Chronic Lymphocytic Leukemia Cells
Authors: Maike Buchner, Natalie Stickel, Arlette Dörffel, Ariane Ott, Marcus Duehren von Minden, Christine Dierks, Hassan Jumaa, Hendrik J. Veelken, Katja Zirlik
Journal: Blood (2011)
Serine Is an Essential Metabolite for Effector T Cell Expansion
Authors: Eric H. Ma, Glenn Bantug, Takla Griss, Stephanie Condotta, Radia M. Johnson, Bozena Samborska, Nello Mainolfi, Vipin Suri, Hannah Guak, Maria L. Balmer, Mark J. Verway, Thomas C. Raissi, Harmony Tsui, Giselle Boukhaled, Sofia Henriques da Costa, Christian Frezza, Connie M. Krawczyk, Adam Friedman, Mark Manfredi, Martin J. Richer, Christoph Hess, Russell G. Jones
Journal: Cell Metabolism (2017)
Biomarker Dynamics in B-cell Lymphoma: A Longitudinal Prospective Study of Plasma Samples Up to 25 Years before Diagnosis
Authors: Florentin Späth, Carl Wibom, Esmeralda J.M. Krop, Ann-Sofie Johansson, Ingvar A. Bergdahl, Roel Vermeulen, Beatrice Melin
Journal: Cancer Research (2017)

The B-cell activation markers CXCL13, sCD23, sCD27, and sCD30 are associated with future lymphoma risk. However, a lack of information about the individual dynamics of marker-disease association hampers interpretation. In this study, we identified 170 individuals who had donated two prediagnostic blood samples before B-cell lymphoma diagnosis, along with 170 matched cancer-free controls from the Northern Sweden Health and Disease Study. Lymphoma risk associations were investigated by subtype and marker levels measured at baseline, at the time of the repeated sample, and with the rate of change in the marker level. Notably, we observed strong associations between CXCL13, sCD23, sCD27, and sCD30 and lymphoma risk in blood samples collected 15 to 25 years before diagnosis. B-cell activation marker levels increased among future lymphoma cases over time, while remaining stable among controls. Associations between slope and risk were strongest for indolent lymphoma subtypes. We noted a marked association of sCD23 with chronic lymphocytic leukemia (ORSlope = 28, Ptrend = 7.279 × 10-10). Among aggressive lymphomas, the association between diffuse large B-cell lymphoma risk and slope was restricted to CXCL13. B-cell activation seemed to play a role in B-cell lymphoma development at early stages across different subtypes. Furthermore, B-cell activation presented differential trajectories in future lymphoma patients, mainly driven by indolent subtypes. Our results suggest a utility of these markers in predicting the presence of early occult disease and/or the screening and monitoring of indolent lymphoma in individual patients. Cancer Res; 77(6); 1408-15. ©2017 AACR.
Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene
Authors: Riccardo Masetti, Salvatore Nicola Bertuccio, Annalisa Astolfi, Francesca Chiarini, Annalisa Lonetti, Valentina Indio, Matilde De Luca, Jessica Bandini, Salvatore Serravalle, Monica Franzoni, Martina Pigazzi, Alberto Maria Martelli, Giuseppe Basso, Franco Locatelli, Andrea Pession
Journal: Journal of Hematology & Oncology (2017)

CBFA2T3-GLIS2 is a fusion gene found in 17% of non-Down syndrome acute megakaryoblastic leukemia (non-DS AMKL, FAB M7) and in 8% of pediatric cytogenetically normal acute myeloid leukemia (CN-AML, in association with several French-American-British (FAB) subtypes). Children with AML harboring this aberration have a poor outcome, regardless of the FAB subtype. This fusion gene drives a peculiar expression pattern and leads to overexpression of some of Hedgehog-related genes. GLI-similar protein 2 (GLIS2) is closely related to the GLI family, the final effectors of classic Hedgehog pathway. These observations lend compelling support to the application of GLI inhibitors in the treatment of AML with the aberration CBFA2T3-GLIS2. GANT61 is, nowadays, the most potent inhibitor of GLI family proteins.We exposed to GANT61 AML cell lines and primary cells positive and negative for CBFA2T3-GLIS2 and analyzed the effect on cellular viability, induction of apoptosis, cell cycle, and expression profile.As compared to AML cells without GLIS2 fusion, GANT61 exposure resulted in higher sensitivity of both cell lines and primary AML cells carrying CBFA2T3-GLIS2 to undergo apoptosis and G1 cell cycle arrest. Remarkably, gene expression studies demonstrated downregulation of GLIS2-specific signature genes in both treated cell lines and primary cells, in comparison with untreated cells. Moreover, chromatin immunoprecipitation analysis revealed direct regulation by GLIS2 chimeric protein of DNMT1 and DNMT3B, two genes implicated in important epigenetic functions.Our findings indicate that the GLI inhibitor GANT61 may be used to specifically target the CBFA2T3-GLIS2 fusion gene in pediatric AML.
Long-Term Follow-Up Results of the Combination of Topotecan and Cytarabine and Other Intensive Chemotherapy Regimens in Myelodysplastic Syndrome.
Authors: Elias Jabbour, Hagop Kantarjian, Miloslav Beran, Jorge Cortes, Susan O’Brien, Francis Giles, Sherry Pierce, Jianqin Shan, William Plunkett, Michael Keating, Elihu Estey
Journal: Blood (2005)
Trolley waits in England rise sixfold in six years, show latest figures
Authors: Nigel Hawkes
Journal: BMJ (2017)

As the war of words over NHS financing becomes increasingly bitter,12 the statistics that track its performance have acquired a prominence they last enjoyed in the late 1990s, when Tony Blair’s first government was struggling to meet its promise to cut waiting lists.

A huge quantity of data are published by the NHS in England covering all parts of the service. As in the 1990s, the keenest attention is always paid to hospital performance, where data on key measures are published monthly. The latest release, covering the period to the end of November 2016, appeared on 12 January.3

The NHS Constitution sets the standard that 95% of patients attending hospital accident and emergency departments should be seen, admitted, or discharged within four hours. In July 2016 NHS Improvement changed the rules slightly, saying that for 2016-17 the aim of hospital trusts should be to improve so that by quarter 4 they could once more meet the standard. So they will be judged in the short term by their rate of improvement, rather than by whether they hit the target.

In …
The prevalence of lymph node metastases in clinical T1N0 thoracic esophageal cancer from the results of JCOG0502.
Authors: Yasunori Akutsu, Ken Kato, Hiroyasu Igaki, Yoshinori Ito, Isao Nozaki, Hiroyuki Daiko, Masahiko Yano, Harushi Udagawa, Satoru Nakagawa, Masakazu Takagi, Hiroshi Okabe, Tetsuya Abe, Tetsu Nakamura, Jun Hihara, Yasushi Toh, Yuichi Shibuya, Junki Mizusawa, Hiroshi Katayama, Kenichi Nakamura, Yuko Kitagawa
Journal: Journal of Clinical Oncology (2015)

10 Background: Recently, a limited operation to avoid needless lymph node (LN) dissection in clinical T1bN0 esophageal cancer (EC) is considered. However, how LN dissection or radiation field should be decided for such cases has not yet been clarified. The information about prevalence of LN metastases (LNMs) would be valuable when the radiation field and extent of LN dissection are considered in the treatment of T1bN0 EC. Methods: JCOG0502 is a randomized controlled trial including a patient preference arm comparing surgery alone to definitive chemoradiotherapy in clinical T1bN0 EC. By using baseline clinical and pathological data of JCOG0502, diagnosis accuracy of LNM was evaluated by comparing clinical and pathologic findings. Then, the sites of pathologic LNMs were determined and the initial sites and the prevalence of LNM were estimated. Results: Between Dec 2006 and Feb 2013, 213 patients (pts) enrolled to the surgery arm in JCOG0502. Pts with multiple lesions or without esophagectomy were excluded and remaining 186 pts were analyzed. Of the 186 pts of clinical T1bN0, 137 pts were diagnosed as LNM negative (73.7%: accuracy of diagnosis), however, 49 pts (26.3%) had pathologic LNMs. Pathologic LNMs were seen at 106recR, 106recL (all in mediastinal region) in upper thoracic (Ut) EC, 101R, 101L, 104R, 104L (in the neck region), 106recR, 106recL, 106tbL, 105, 107, 108, 109L, 110 (in the mediastinal region), 1,2,3,7, 11 (in the abdominal region) in middle thoracic (Mt) EC, and 105, 106recL, 110 (in the mediastinal region), 1, 2, 3, 7 (in the abdominal region) in lower thoracic (Lt) EC, respectively. Of the 49 pts who had pathologic LNMs, 32 pts (65%) were of pathologically N2 or more. Furthermore, 18 pts (37%) had skip LNM (LNM of N2, N3 or N4 without N1). The solitary pathologic LNM was observed in 25 pts: N1 (106recR, 106recL) in Ut, N1 (106recR, 106recL, 108), N2 (101R, 105, 110, 1, 3, 7), in Mt, N1(110, 1), N2 (106recL, 3, 7) in Lt, respectively. Conclusions: In the current status of clinical diagnosis, limited LN dissection or limited field of radiation are not recommended. In surgery, D2 LN dissection is necessary and three-field LN dissection is recommended especially in middle thoracic EC even for clinical T1bN0. Clinical trial information: UMIN000000551.
Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naive Patients Aged ≥65 Years with Acute Myeloid Leukemia
Authors: Andrew Wei, Stephen A. Strickland, Gail J. Roboz, Jing-Zhou Hou, Walter Fiedler, Tara L. Lin, Giovanni Martinelli, Roland B. Walter, Anoop Enjeti, Kaffa Fakouhi, David E. Darden, Martin Dunbar, Ming Zhu, Suresh Agarwal, Ahmed H. Salem, Mack Mabry, John Hayslip
Journal: Blood (2016)
A Phase 1/2 Study of Carfilzomib As a Replacement for Bortezomib for Multiple Myeloma (MM) Patients (pts) Refractory to a Bortezomib-Containing Combination Regimen
Authors: James R. Berenson, James D. Hilger, Robert Dichmann, Dipti Patel-Donnelly, Ralph V. Boccia, Alberto Bessudo, Laura V. Stampleman, Donald S. Gravenor, Shahrooz Eshaghian, Youram Nassir, Regina A. Swift, Robert Vescio
Journal: Blood (2012)
Goserelin plus anastrozole as first-line endocrine therapy for premenopausal women with oestrogen receptor (ER) positive advanced breast cancer (ABC)
Authors: K.-L. Cheung, L. Winterbottom, R. Owers, J. Robertson
Journal: Journal of Clinical Oncology (2005)

731 Background We have previously reported the use of goserelin plus anastrozole as second-line endocrine therapy for premenopausal women with ER-positive ABC. With randomised data showing superiority of third-generation aromatase inhibitors over tamoxifen as first-line therapy for postmenopausal women with ER-positive ABC, we now report our clinical experience of using anastrozole alongside ovarian suppression (with goserelin) in the same setting in premenopausal women. Methods Twenty premenopausal patients (mean age = 42 (30 - 57) years) (advanced primary = 3, soft tissue = 2, bone = 8, pleura/lung = 3, stomach = 1, liver = 2, bone + liver = 1) with ER-positive ABC seen over a 3-year period were treated with goserelin 3.6 mg 4-weekly plus anastrozole 1 mg daily as first-line therapy. Endocrine therapy was considered therapy of choice except in two patients with liver metastases who did not have chemotherapy due to pulmonary embolism or patient choice. All have disease assessable by UICC criteria and have received the therapy for at least 6 months (except for those who progressed prior). Results Twelve patients (60%) derived clinical benefit (CB) (objective response or durable stable disease for at least 6 months) while eight progressed before 6 months. For the 12 patients who have derived CB, the median duration of response is 20+ months (range: 6 - 36 months). At the time of analysis, therapy is continuing in nine patients. When the two patients with liver metastases for whom chemotherapy was therapy of choice were excluded, the CB rate rose to 66%. Therapy has been well tolerated and no patients came off it because of side effects. Conclusion A combined use of goserelin and anastrozole produces CB with long duration in significant proportion of premenopausal women with ER-positive ABC when used as first-line therapy. Further studies with more patients and longer follow-up are warranted. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration AstraZeneca
Global Gene Expression Signatures in CD34+ Hematopoietic Cells Following Exposure to 16,16-Dimethylprostaglandin E2.
Authors: Robyn S. Allen, Ping Jin, Trista North, Wolfram Goessling, Yu Tian, Mark E. Metzger, Aylin C. Bonifacino, David Stroncek, Leonard I. Zon, Robert E. Donahue
Journal: Blood (2009)
Cyclophosphamide treatment and reconstitution with peripheral blood mononuclear cells does not reduce the frequency of circulating FoxP3 cells in vaccinated prostate cancer patients
Authors: Ilka Assmann, Daniel Haley, Tarsem Moudgil, Christian Poehlein, Hong-Ming Hu, Edwin Walker, Nathalie Sacks, Kristen Hege, Brendan Curti, Walter J. Urba, Bernard A. Fox
Journal: Cancer Research (2006)

Proc Amer Assoc Cancer Res, Volume 47, 2006

2898 

Carcinoma of the prostate is the most common form of cancer of the adult male in the US. While hormonal therapy offers excellent palliation in over 75% of cases, no curative therapy exists for hormone refractory metastatic prostate carcinoma. Dismal treatment options coupled with the unique biology of the prostate makes it particularly well suited to vaccine strategies.A potential strategy to optimize vaccines for prostate cancer may be to vaccinate during a period of homeostasis-driven proliferation, when T cells are hyper responsive to antigenic stimulation. This strategy has the theoretical advantages that it will reduce the activation threshold of T cells, eliminate regulatory T cells (Treg), and increase space and access to cytokines. In preclinical studies we have modeled this by vaccinating, with a GM-CSF-secreting tumor vaccine, lymphopenic mice that have been reconstituted with 10-20 x 106 spleen cells. This strategy provides the host with a diverse T cell repertoire and results in augmented priming of tumor-specific T cells with increased therapeutic efficacy. We have initiated a randomized Phase I/II clinical trial that translates this strategy into patients with progressive, metastatic hormone-refractory adenocarcinoma of the prostate. Cohort A patients receive GVAX A‘Â® vaccine for prostate cancer (two prostate cancer cell lines modified to secrete GM-CSF, Cell Genesys Inc.) and cohort B (n = 3) received 350 mg/m2 cyclophosphamide for 3 days followed by reinfusion of autologous PBMCs in addition to vaccination. To date, 6 patients have been randomized to cohort A or B and all have provided written informed consent. Multi-parameter flow cytometer analysis was performed on baseline (pre treatment) and post treatment (Day 14) PBMCs to measure changes in CD4+CD25+FoxP3+ and CD4+CD25-FoxP3+ subsets. Preliminary results suggest that there was an increase in the frequency of FoxP3+ cells in both cohorts. PCR confirmation and functional studies are underway, but these data suggest that additional interventions may be required to reduce regulatory T cells in this patient population. Supported by DAMD grant PC020094 and generous support of Mr. Tom Denhart, the Chiles Foundation and the Murdock Trust.
Anti-Myeloma Activity of LDC-000067, a Novel Selective Inhibitor of Cyclin Dependent Kinase 9: A Targeted Approach
Authors: Kathrin Niepoth, Dirk Gustavus, Doris Wenning, Michael Meisterernst, Joachim Kienast, Wolfgang E. Berdel, Guido Bisping
Journal: Blood (2011)
Mimicking the Hematopoietic Niche Microenvironment Provides a Novel Strategy for Expansion of Hematopoietic and Megakaryocyte-Progenitor Cells from Cord Blood
Authors: Varda R Deutsch, Einav Hubel, Sigi Kay, Tal Ohayon, Ben-Zion Katz, Elizabeth Naparstek, Dan Grisaru
Journal: Blood (2008)
Highly Sensitive Bioluminescence in Vivo Imaging Enables Individualized Preclinical Treatment Trials On Patients ALL Tumor Cells Growing in Mice.
Authors: Nadia Terziyska, Catarina Castro Alves, Manfred Ogris, Ernst Wagner, Renier J Brentjens, Martin A. Horstmann, Leticia Quintanilla-Martinez, Irmela Jeremias
Journal: Blood (2012)
Second Reduced Intensity Transplants Are Effective and Well Tolerated in Older Patients with Relapsed Myeloid Malignancies. A Single Centre Report.
Authors: Frederick E. Chen, Humayun N. Ahmad, Pritesh Junagade, Zi Lim, Stephen Devereux, Antonio Pagliuca, Aloysius Ho, Ghulam J. Mufti
Journal: Blood (2005)
Expression of Activation-Induced Cytidine Deaminase and Transcripts of Immunoglobulin Variable Heavy Chains in Mature B-Cell Lines Lacking Immunoglobulin Protein Expression.
Authors: Yoshinobu Matsuo, Hans G. Drexler, Akira Harashima, Ayumi Okochi, Masanori Daibata, Tetsuya Takakuwa, Kunzo Orita
Journal: Blood (2004)
Pomegranate LTP isoforms identified by a new proteomic approach show different immunological properties
Authors: G. Zoccatelli, M. Consolini, M. Fusi, C. Dalla Pellegrina, R. Chignola, A. Peruffo, F. Marsano, M. San Miguel-Moncin, S. Scheurer, C. Rizzi
Journal: Allergy (2008)
Comparison between Anti-Thymocyte Globulin and Alemtuzumab and the Possible Impact of KIR-Ligand Mismatch in Melphalan/Fludarabine Dose-Reduced Conditioning Followed by HLA-Matched and Mismatched Unrelated Stem Cell Transplantation in Patients with Multiple Myeloma.
Authors: Nicolaus Kroeger, Brownen Shaw, Simona Iacobelli, Tatjana Zabelina, Karl Peggs, Avichai Shimoni, Arnon Nagler, Thomas Binder, Rainer Schwerdtfeger, Michael Kiehl, Herbert G. Sayer, Francis Ayuk, Thomas Eiermann, David Marks
Journal: Blood (2004)
Thrombopoietin (TPO) Induces Hematopoietic Differentiation of Mouse ES Cells Via HIF-1 Alpha-Dependent Activation of a BMP4 Autoregulatory Loop
Authors: Azadeh Zahabi, Tatsuya Morishima, Andri Pramono, Dan Lan, Lothar Kanz, Karl Welte, Julia Skokowa
Journal: Blood (2015)
Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile–based classification
Authors: Laura K. Ferris, Aaron S. Farberg, Brooke Middlebrook, Clare E. Johnson, Natalie Lassen, Kristen M. Oelschlager, Derek J. Maetzold, Robert W. Cook, Darrell S. Rigel, Pedram Gerami
Journal: Journal of the American Academy of Dermatology (2017)

A significant proportion of patients with American Joint Committee on Cancer (AJCC)-defined early-stage cutaneous melanoma have disease recurrence and die. A 31-gene expression profile (GEP) that accurately assesses metastatic risk associated with primary cutaneous melanomas has been described.We sought to compare accuracy of the GEP in combination with risk determined using the web-based AJCC Individualized Melanoma Patient Outcome Prediction Tool.GEP results from 205 stage I/II cutaneous melanomas with sufficient clinical data for prognostication using the AJCC tool were classified as low (class 1) or high (class 2) risk. Two 5-year overall survival cutoffs (AJCC 79% and 68%), reflecting survival for patients with stage IIA or IIB disease, respectively, were assigned for binary AJCC risk.Cox univariate analysis revealed significant risk classification of distant metastasis-free and overall survival (hazard ratio range 3.2-9.4, P < .001) for both tools. In all, 43 (21%) cases had discordant GEP and AJCC classification (using 79% cutoff). Eleven of 13 (85%) deaths in that group were predicted as high risk by GEP but low risk by AJCC.Specimens reflect tertiary care center referrals; more effective therapies have been approved for clinical use after accrual.The GEP provides valuable prognostic information and improves identification of high-risk melanomas when used together with the AJCC online prediction tool.